Russian government plans on innovative drugs and centralized mechanism for their purchase

16 February 2018

The Russian Federal Anti-Monopoly Service (FAS) has announced its plans to submit a proposal to the national government to speed up state registration of innovative drugs and to create a centralized mechanism for their purchase in the country, according to an official spokesman of head of FAS Sergey Artemyev, reports The Pharma Letter’s local correspondent.

At present state procurement of drugs is the second largest (after construction) cost item for state customers. According to the Ministry of Economics, in 2016, the value of this segment reached 550 billion roubles ($9.48 billion).

Most of the purchases are carried out by regional health ministries and health facilities. The fragmentation of the segment of public purchases of drugs was one of the goals of a new public procurement system, which was established in Russia in 2014, with the aim of stimulating competition in the state segment of the Russian pharmaceutical market and reduce prices for drugs sold within it.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK